

10. van der Peet DL, Klinkenberg-Knol EC, Berends FJ, Cuesta MA. Epiphrenic diverticula: minimal invasive approach and repair in five patients. *Dis Esophagus*. 2001;14:60–2.
11. Neoral C, Aujesky R, Bohanes T, Klein J, Kral V. Laparoscopic transhiatal resection of epiphrenic diverticulum. *Dis Esophagus*. 2002;15:323–5.
12. Champion JK. Thoracoscopic Belsey fundoplication with 5-year outcomes. *Surg Endosc*. 2003;17:1212–5.
13. Fraiji E Jr, Bloomston M, Carey L, Zervos E, Goldin S, Banasiak M, et al. Laparoscopic management of symptomatic achalasia associated with epiphrenic diverticulum. *Surg Endosc*. 2003;17:1600–3.
14. Pitchford TJ, Price PD. Laparoscopic Heller myotomy with epiphrenic diverticulectomy. *JLS*. 2003;7:165–9.
15. Costantini M, Zaninotto G, Rizzetto C, Narne S, Ancona E. Oesophageal diverticula. *Best Pract Res Clin Gastroenterol*. 2004;18:3–17.
16. Del Genio A, Rossetti G, Maffetton V, Renzi A, Bruscianno L, Limongelli P, et al. Laparoscopic approach in the treatment of epiphrenic diverticula: long-term results. *Surg Endosc*. 2004;18:741–5.
17. Fernando HC, Luketich JD, Samphire J, Alvelo-Rivera M, Christie NA, Buenaventura PO, et al. Minimally invasive operations for esophageal diverticula. *Ann Thorac Surg*. 2005;80:2076–80.
18. Tedesco P, Fisichella PM, Way LW, Patti MG. Cause and treatment of epiphrenic diverticula. *Am J Surg*. 2005;190:891–4.
19. Valentini M, Pera M, Vidal O, Lacima G, Belda J, de Lacy AM. Incomplete esophageal myotomy and early recurrence of an epiphrenic diverticulum. *Dis Esophagus*. 2005;18:64–6.
20. Feo CV, Sortini D, Liboni A. Oesophageal achalasia with epiphrenic diverticulum with laparoscopic approach: a 6-year follow-up. *Dig Surg*. 2006;23:27.
21. Motoyama S, Maruyama K, Okuyama M, Sasaki K, Sato Y, Ogawa J. Laparoscopic long esophagomyotomy with Dor fundoplication using a transhiatal approach for an epiphrenic esophageal diverticulum. *Surg Today*. 2006;36:758–60.
22. Granderath FA, Pointner R. Laparoscopic transhiatal resection of giant epiphrenic esophageal diverticulum. *Dis Esophagus*. 2007;20:353–7.
23. Kinoshita Y, Udagawa H, Tsutsumi K, Ueno M, Mine S, Ehara K, et al. Modified Dor fundoplication technique following diverticulectomy and myotomy for epiphrenic diverticulum combined with esophageal motility disorders: prevention of esophageal leak at the diverticulectomy staple line. *Esophagus*. 2008;5:57–60.
24. Miyashita M, Ohkawa K, Akagi I, Nomura T, Makino H, Tajiri T. Esophagoscopy-guided thoracoscopic resection of large epiphrenic esophageal diverticulum. *Esophagus*. 2008;5:225–8.
25. Palanivelu C, Rangarajan M, John SJ, Parthasarathi R, Senthilkumar R. Laparoscopic transhiatal approach for benign supra-diaphragmatic lesions of the esophagus: a replacement for thoracoscopy? *Dis Esophagus*. 2008;21:176–80.
26. Palanivelu C, Rangarajan M, Maheshkumar GS, Senthilkumar R. Minimally invasive surgery combined with perioperative endoscopy for symptomatic middle and lower esophageal diverticula: a single institute's experience. *Surg Laparosc Endosc Percutan Tech*. 2008;18:133–8.
27. Silecchia G, Casella G, Recchia CL, Bianchi E, Lomartire N. Laparoscopic transhiatal treatment of large epiphrenic esophageal diverticulum. *JLS*. 2008;12:104–8.
28. Melman L, Quinlan J, Robertson B, Brunt LM, Halpin VJ, Eagon JC, et al. Esophageal manometric characteristics and outcomes for laparoscopic esophageal diverticulectomy, myotomy, and partial fundoplication for epiphrenic diverticula. *Surg Endosc*. 2009;23:1337–41.
29. Nehra D, Lord RV, DeMeester TR, Theisen J, Peters JH, Crookes PF, et al. Physiologic basis for the treatment of epiphrenic diverticulum. *Ann Surg*. 2002;235:346–54.
30. Allen TH, Clagett OT. Changing concepts in the surgical treatment of pulsion diverticula of the lower esophagus. *J Thorac Cardiovasc Surg*. 1965;50:455–62.
31. Fekete F, Vonns C. Surgical management of esophageal thoracic diverticula. *Hepatogastroenterology*. 1992;39:97–9.
32. Evander A, Little AG, Ferguson MK, Skinner DB. Diverticula of the mid- and lower esophagus: pathogenesis and surgical management. *World J Surg*. 1986;10:820–8.
33. Rosati R, Fumagalli U, Bona S, Bonavina L, Peracchia A. Diverticulectomy, myotomy, and fundoplication through laparoscopy: a new option to treat epiphrenic esophageal diverticula? *Ann Surg*. 1998;227:174–8.
34. Belsey R. Functional disease of the esophagus. *J Thorac Cardiovasc Surg*. 1966;52:164–88.
35. Effler DB, Barr D, Groves LK. Epiphrenic diverticulum of the esophagus: surgical treatment. *Arch Surg*. 1959;79:459–67.
36. Kjellin AP, Granqvist S, Ramel S, Thor KB. Laparoscopic myotomy without fundoplication in patients with achalasia. *Eur J Surg*. 1999;165:1162–6.
37. Wang PC, Sharp KW, Holzman MD, Clements RH, Holcomb GW, Richards WO. The outcome of laparoscopic Heller myotomy without antireflux procedure in patients with achalasia. *Am Surg*. 1998;64:515–20.
38. Richards WO, Torquati A, Holzman MD, Khaitan L, Byrne D, Lutfi R, et al. Heller myotomy versus Heller myotomy with Dor fundoplication for achalasia: a prospective randomized double-blind clinical trial. *Ann Surg*. 2004;240:405–12.
39. Gawande AS, Batiuchok W, Barman AA, Mule JE. Carcinoma within lower esophageal (epiphrenic) diverticulum. *N Y State J Med*. 1972;72:1749–51.
40. Fujita H, Kakegawa T, Shima S, Kumagaya Y. Carcinoma within a middle esophageal (parabronchial) diverticulum: a case report and the review of the literature. *Jpn J Surg*. 1980;10:142–8.

Molecular Approaches and Modern Clinical Strategies for the Management of *Helicobacter pylori* Infection in Japan

Hidekazu Suzuki,¹ Toshihiro Nishizawa,² Hitoshi Tsugawa¹ and Toshifumi Hibi¹

¹ Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan

² Division of Gastroenterology, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan

(Received for publication on February 13, 2012)

(Revised for publication on February 28, 2012)

(Accepted for publication on March 21, 2012)

Thirty years have passed since Warren and Marshall's discovery of *Helicobacter pylori* (*H.pylori*). Since then, not only peptic ulcer diseases and chronic gastritis but also non-cardia gastric cancers have been recognized as diseases originating from *H. pylori* infection. Several combination therapies consisting of multiple antibiotics have been developed as first- or second-line regimens to eradicate *H. pylori* infection. Our extensive experience in the field of anti-*H. pylori* medicine suggests that clinicians should consider a possible role for unidentified, invisible pathogens to elucidate the pathogenesis and improve the treatment of refractory diseases of unknown etiology. (doi: 10.2302/kjm.2012-0001-RE; Keio J Med 61 (4) : 109–119, December 2012)

Keywords: *Helicobacter pylori*, CagA, indication, diagnosis, eradication

Introduction

Classical bacteriology techniques have demonstrated that *Helicobacter pylori* (*H.pylori*) is a gram-negative, flagellated bacterium that expresses catalase and urease, enzymes which help neutralize host responses and enable intragastric colonization. One of the early benefits of this basic research was the realization that virtually all strains of *H. pylori* produce urease. This finding led to the development of accurate diagnostic tests, including the rapid urease test and the urea breath test. A stool antigen test has also emerged as an informative, noninvasive means by which to diagnose infection via detection of bacterial antigens.

Before the discovery of intragastric bacteria 30 years ago, there were several reports of spiral gastric bacteria dating back to 1890 (Table 1).¹ The modern discovery of *H. pylori* may have been delayed by Palmer's declaration in 1954 that there were no microorganisms in the human stomach. At that time, microorganisms were believed to be unable to survive in the acidic gastric environment,

and intragastric spiral bacteria had been observed only post-mortem;² however, the presence of organisms in the gastric mucosa had been described since the 1890s. In Japan, Kasai and Kobayashi of the Kitasato Institute reported propagation of a spirochete-like organism, probably modern *Helicobacter felis*, from the stomachs of dogs and cats but not from laboratory animals.³ They showed that when rabbits infected with these spirochetes were inoculated with *virus fixe*, marked hemorrhagic lesions were produced in the gastric mucosa. In addition, spirochetes inoculated into the mouse gastric mucosa could be eradicated by arsaminol (a classic equivalent of bismuth).⁴ Sixty five years later, scientists and doctors again attempted to treat gastric diseases associated with "spirochetes," i.e., *Helicobacter pylori* infection. To commemorate the achievements of Kobayashi and coworkers in the Taisho era, the Rokuzo Kobayashi Memorial Symposium on *Helicobacter pylori* was held on May 11th, 2002, in Kita-kan Hall at Keio University Mita Campus, Tokyo, Japan.^{4,5}

Table 1 History of *Helicobacter* research

1892	Bizzozzo	Discovery of snake-like bodies in a dog stomach
1906	Krienitz	Discovery of spirochete-like bodies in human stomach
1919	Kasai and Kobayashi	Establishment of an animal model for <i>H. felis</i> infection and first <i>Helicobacter</i> eradication experiment
1938	Doenges	Isolation of spirochete-like organism from a human stomach
1954	Palmer	Denied the existence of microorganisms in the stomach
1976	Lieber	Reduction of gastric NH ₃ by ampicillin
1982	Warren and Marshall	Detection and isolation of <i>Campylobacter</i> -like organism from biopsied gastric specimens (<i>Campylobacter pyloridis</i>)
1994	NIH Consensus Development Conference	Recommendation of <i>H. pylori</i> eradication therapy for all patients with peptic ulcer disease
2002	Marshall	Keio Medical Science Prize
2005	Warren and Marshall	Nobel Prize in Physiology and Medicine

Pathogenesis

The most-investigated bacterial toxins of *H. pylori* are associated with a segment of bacterial DNA referred to as the *cag* pathogenicity island (*cag* PAI). Genes within the *cag* PAI encode proteins such as CagE, an ATPase that drives a type IV secretory apparatus enabling bacterial macromolecules, especially the toxin CagA, to translocate into the host cell. The intact *cag* PAI of *H. pylori* plays a significant role in the pathogenesis of chronic gastritis in humans because the *cag* PAI is associated with increased chemokine expression and greater inflammation in gastric mucosal specimens.⁶ After the CagA protein is injected into the host cell cytoplasm through the type IV secretory system, the EPIYA motif of CagA is tyrosine-phosphorylated by host Src kinases, and the phosphorylated protein subsequently alters the gastric epithelial morphology. Src homology-2 domain-containing phosphatase 2 (SHP2) is able to bind the EPIYA-B, EPIYA-C, and EPIYA-D motifs.⁷ Importantly, however, CagA with the EPIYA-D motif has a higher binding affinity for SHP2 than does CagA with the EPIYA-C motif.⁸ The sequence flanking the tyrosine phosphorylation site of the EPIYA-D motif (EPIYATIDF), but not that flanking of the EPIYA-C motif (EPIYATIDD), perfectly matches the consensus high-affinity binding sequence for the SH2 domains of SHP2. The CagA proteins of strains from distinct geographic populations appear to be phosphorylated to different degrees, resulting in graded effects on intracellular signaling.⁹

The biological half-life of intracellular CagA in gastric epithelial cells was recently reported to be approximately 200 min,¹⁰ and the activity of CagA as an epigenetic oncoprotein thus does not persist for a long period in any single cell. Therefore, the risk of gastric cancer may be determined by various factors that influence the stability of intracellular CagA. We recently reported that intracellular CagA is degraded by p53 degradation-induced au-

tophagy;¹¹ however, a specific mutation in p53 increases the intracellular stability of CagA by inhibiting its autophagic degradation. These findings suggest that disrupting the autophagic degradation of CagA increases the risk of developing *H. pylori*-associated gastric cancer.

VacA is the second-most extensively studied *H. pylori* virulence factor. In addition to inducing vacuolation, VacA also promotes several cellular activities, including membrane channel formation and the release of cytochrome *c* from mitochondria and consequent apoptosis. VacA can also specifically inhibit T-cell activation and proliferation.¹² Further studies have confirmed that the risks for both cancer and peptic ulcers are associated strongly with the *cagA/vacA s1m1* genotype but rarely with the *vacA s2m2* polymorphism.¹³

Oxygen-derived free radicals released from activated neutrophils extravasated from microvascular beds are considered to be potential toxic factors involved in *H. pylori*-induced gastric mucosal injury because *H. pylori* exhibits chemotactic activity for neutrophils.^{1,14} Neutrophil infiltration of the gastric mucosa leads to the development of the initial lesions of *H. pylori*-associated gastritis. Neutrophils express the enzyme myeloperoxidase, which, in the presence of Cl⁻, produces the potent oxidant hypochlorous anion (OCl⁻) from H₂O₂. This hypochlorous anion reacts with ammonia, produced from urea by *H. pylori*-associated urease, to yield the lipophilic cytotoxic oxidant monochloramine (NH₂Cl), which freely penetrates biological membranes to oxidize intracellular components (Fig. 1, left).¹ 8-Hydroxy-2-deoxyguanosine (8-OHdG), which results from the attack of a singlet hydroxyl or oxygen radical on guanine, is one of the forms of DNA damage most commonly induced by reactive oxygen species. Patients with *cagA*-positive strains of *H. pylori* have higher 8-OHdG levels than do *cagA*-negative or *H. pylori*-negative patients.¹⁵ We previously reported greater enhancement of neutrophil-derived gastric mucosal luminol-dependent chemiluminescence levels in




Fig. 1 Molecular approaches to *Helicobacter pylori* infection.

RdxA, NADPH nitroreductase; Fur, ferric uptake regulator; FecA1, a Fe^{3+} -dicitrate transporter homolog.

cagA-positive patients than in *cagA*-negative patients.¹⁶ *cagA*-positive patients are characterized by greater oxidative DNA damage, both overall and at younger ages, in the presence of multifocal atrophy.

Infection of gastric epithelial cells with *H. pylori* increases the accumulation of intracellular reactive oxygen species (ROS). Increased intracellular oxidative stress may play a role in the induction of programmed cell death.¹⁷ We recently detected increased mitochondrial ROS production in *H. pylori*-infected gastric epithelial cells. This finding suggests that *H. pylori* infection alters the mitochondria. In addition, the antioxidant *N*-acetyl cysteine inhibited induction of autophagy and induced the accumulation of intracellular CagA.¹¹ These results suggest that intracellular oxidative stress is involved in the induction of autophagy required for CagA degradation (Fig. 1, lower right).¹¹

Metronidazole, a major component of the second-line *H. pylori* eradication regimen used in Japan, enters cells by diffusion, and its antimicrobial toxicity depends on the reduction of its nitro group to nitro anion radicals and the subsequent generation of superoxide radicals (O_2^-).^{18,19} In

detail, the NADPH nitroreductase of *H. pylori* reduces the nitro group of metronidazole to anion radicals that induce oxidative stress and produce DNA strand breaks, causing rapid cell death.¹⁸ *H. pylori* expresses only a single superoxide dismutase, the iron-cofactored enzyme SodB, which has 53.5% identity with the *Escherichia coli* protein FeSod.²⁰ SodB prevents the interaction between iron and superoxide and also catalyzes the dismutation of superoxide (O_2^-) into oxygen (O_2) and hydroperoxide (H_2O_2). The mRNA expression of *sodB* in *H. pylori* is directly regulated by the ferric uptake regulator (Fur) protein.²¹ We recently found metronidazole-resistant strains of *H. pylori* with amino acid mutations in Fur that significantly reduced its binding affinity for its operator sequence in the *sodB* promoter (Fur-Box), resulting in derepression of *sodB* mRNA expression.²² In other words, metronidazole resistance is due to enhanced scavenging activity of cytotoxic superoxide (O_2^-), a major bactericidal component of metronidazole, because of the derepression of *H. pylori* SodB expression by mutant Fur (Fig. 1, left).²²

Ferrous iron (Fe^{2+}), an essential cofactor for many enzymes and metalloproteins, is necessary for the basal

functions of all cells as well as for SodB activation.²³ We recently demonstrated that the FecA1 protein, a Fe³⁺-dicitrate transporter homolog, is essential for SodB activation but not for the bioactivity of *H. pylori*.²⁴ *fecA1* mRNA expression is derepressed in metronidazole-resistant *H. pylori* strains with mutations in Fur.²⁴ Deletion of *fecA1* dramatically decreased the minimal inhibitory concentrations (MICs) of metronidazole for *H. pylori* strains with Fur mutations,²⁴ suggesting that the activation of SodB by mutant Fur is supported by the FecA1-dependent Fe²⁺ supply system (Fig. 1, upper right).

Notably, *in vitro* study has shown that metronidazole-susceptible *H. pylori* became metronidazole resistant after several passages on agar plates containing sub-inhibitory concentrations of metronidazole.²⁵ From these findings, it can be readily assumed that metronidazole-susceptible *H. pylori* may become metronidazole resistant through repeated exposure to sub-inhibitory concentrations of metronidazole. Therefore, it is important to understand the initial anti-metronidazole response of metronidazole-susceptible *H. pylori* to prevent the acquisition of resistance and consequent increased incidence of metronidazole-resistant *H. pylori*.

Five families of multidrug efflux transporters have been described in bacteria.²⁶ One of these five efflux systems, the RND family, has three components, namely, the inner membrane efflux proteins, a periplasmic efflux protein, and an outer membrane efflux protein (the TolC, or TolC homolog protein).²⁷ Four RND families have been identified in *H. pylori* (HP0605 to HP0607; HefABC and HP0971 to HP0969; HefDEF and HP1327 to HP1329; HefGHI and HP1489 to HP1487), and these proteins are reportedly involved in the development of multidrug resistance.²⁸ We recently explored the variations in transcription of the RND efflux pump systems in the initial phases of the development of metronidazole resistance *in vitro*. In this study, the MICs of metronidazole for 9 out of 10 metronidazole-susceptible strains cultured on plates containing sub-inhibitory concentrations of metronidazole increased to levels similar to those for metronidazole-resistant strains. In the newly metronidazole-resistant strains, exposure to metronidazole significantly increased the expression of the TolC efflux pump (*hefA*) with no decrease in the metronidazole-reduction activity, suggesting that overexpression of the TolC efflux pump *hefA* may be the first step in the acquisition of metronidazole resistance in *H. pylori*.²⁹

***H. pylori* and gastric cancer – molecular approach**

Gastric epithelium changes during the progression from inflammation to cancer, with evidence of disruption of normal epithelial cell differentiation and recruitment of inflammatory cells.³⁰ Coincident with the development of atrophic gastritis and intestinal metaplasia is the loss

of expression of the gastric morphogen sonic hedgehog (Shh).^{31,32} Loss of Shh is reportedly an early change in carcinogenesis of the gastric mucosa, prior to neoplastic transformation. We have demonstrated in humans that the suppression of Shh expression in the gastric mucosa by *H. pylori* infection was restored after eradication of the infection and that earlier eradication more fully restored Shh expression in the gastric mucosa.^{33,34}

MicroRNAs (miRNAs) are post-transcriptional regulators of gene expression that are involved in development, cell proliferation, and immune responses. Recent studies have shown that some miRNAs act as tumor suppressors or oncogenes in gastric cancer.³⁵ Some miRNAs, including *miR-146*, *miR-155*, *miR-21*, *miR-27a*, *miR-106-93-25*, the *miR-221-222* clusters, and the *miR-200* family, are possibly involved in *H. pylori* infection and associated gastric cancers.³⁶ miRNA expression profiling may be a powerful tool for clinical cancer diagnosis, and regulation of miRNA expression could be a novel strategy for the chemoprevention of human gastrointestinal cancers.³⁷

***H. pylori* and gastric mucosa-associated lymphoid tissue lymphoma – molecular approach**

H. pylori eradication has become widely accepted as an initial treatment strategy for stage I gastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT) type. *H. pylori*-positive low-grade gastric MALT lymphoma regresses both endoscopically and histopathologically after *H. pylori* eradication in 60%–80% of such cases.³⁸ The presence of a t(11;18)(q21;q21) translocation appears to be a major predictor of failure to respond. This translocation is associated with an *API2-MALT1* fusion; the former is involved in the regulation of apoptosis, and the latter is a caspase-like protein with an as yet unknown biological function. The fusion causes suppression of apoptosis. Several studies have reported that MALT lymphomas with this translocation respond only rarely or not at all to *H. pylori* eradication.

Methylation of the *p16/INK4a* gene was observed in 60% of MALT lymphomas; however, *p16* gene methylation status did not correlate with the presence of *API2-MALT1* fusion or any other clinicopathological factor, suggesting that aberrant methylation of the *p16* gene might be an early event in MALT lymphomagenesis.³⁹ Examination of the methylation profiles of eight CpG islands, namely *p15*, *p16*, *p73*, *hMLH1*, *DAPK*, *MINT1*, *MINT2*, and *MINT31*, revealed that more than four genes were methylated in *H. pylori*-dependent MALT lymphomas while fewer than two genes were methylated in non-*H. pylori*-dependent cases, indicating that the pathogenesis of gastric MALT lymphomas, including the aberrant DNA methylation pattern, may differ between *H. pylori*-dependent and non-*H. pylori*-dependent cases.⁴⁰ Aberrant DNA methylation thus plays critical roles in the




Fig. 2 New disease entity concept clarifying the difference between *H. pylori*-associated and non-*H. pylori*-associated dyspepsia.^{48,53}

pathogenesis of gastric MALT lymphomas, and determination of the DNA methylation pattern may hold promise as a clinical tool for surveillance of gastric MALT lymphomas.

***H. pylori* and idiopathic thrombocytopenia purpura – molecular approach**

Idiopathic thrombocytopenic purpura (ITP) is a bleeding disorder in which platelet-specific autoantibodies cause platelets to be lost. In a subset of *H. pylori*-infected patients with ITP, the number of platelets recovers after the eradication of *H. pylori*.^{41,42} According to our previous research into the role of *H. pylori* infection in the pathogenesis of ITP,⁴³ a significant increase in platelet numbers was observed after *H. pylori* eradication in 61% of patients. In this study, at baseline, monocytes from *H. pylori*-positive patients exhibited an enhanced phagocytic capacity and low levels of the inhibitory Fc γ receptor IIB (Fc γ RIIB). This activated monocyte phenotype was suppressed 1 week after the start of the *H. pylori* eradication regimen, and this suppression was followed by improvements in other autoimmune and platelet kinetic parameters. *H. pylori* infection was also associated with an altered monocyte Fc γ R balance in individuals without ITP; a similar result was also found in mice. Our findings strongly suggest that the recovery in platelet numbers observed in ITP patients after *H. pylori* eradication is mediated through a shift of the Fc γ R balance toward inhibitory Fc γ RIIB.

Veneri et al. reported that the host factors HLADRB111, HLA-DRB 114, and HLA-DQB 103 occurred at high frequencies in patients with *H. pylori*-positive ITP, while the frequency of the host factor HLA-DRB 103 was higher in the *H. pylori*-negative ITP group than in the *H. pylo-*

ri-positive ITP group. HLA-DQB 103 showed favorable platelet reactivity after *H. pylori* eradication therapy in *H. pylori*-positive ITP patients.⁴⁴

Functional dyspepsia and *H. pylori* infection

Functional dyspepsia (FD) is a condition in which upper abdominal symptoms occur in the absence of any explanatory organic disease.⁴⁵ *H. pylori* infection is not an exclusion criterion for FD under the current Rome III classification.⁴⁵ However, recent advances in basic and clinical research have revealed that *H. pylori* infection plays an important role in the development of gastroduodenal dysmotility and hypersensitivity and also in dyspeptic symptoms.^{46–48} For example, the authors revealed that in mice, chronic *H. pylori* infection downregulates expression of muscle-specific miRNAs (*miR-1*, *miR-133a*, and *miR-133b*) and upregulates expression of their targets, such as histone deacetylase 4 and serum response factor. These transcriptional changes cause hyperplasia of the muscular layer of the stomach and gastric emptying deregulation.⁴⁹ In addition, *H. pylori* eradication therapy appears to have a small but statistically significant effect on FD.^{50,51} Therefore, *H. pylori*-associated dyspepsia (HpD) should be excluded from the umbrella category of FD to better elucidate the pathophysiological mechanisms of FD and to establish more precise diagnostic markers or criteria (**Fig. 2**).^{46,48,52} In Japan, for national insurance claim purposes, *H. pylori*-positive histological gastritis, NSAID-induced gastritis, and neurotic gastritis (or stress-induced gastritis) have all been combined under the diagnosis of “chronic gastritis” and have therefore been treated with the same drugs. Of these groups of diseases, FD would be categorized as classical stress-induced gastritis. However, as each type of gas-




Fig. 3 Numbers of board certified doctors and institutes performing *H. pylori* eradication therapy uncovered by the Japanese national insurance, at the time point of March 2012.

(adopted from the homepage of the JSHR with permission; http://www.jshr.jp/index.php?page=medic_list, http://www.jshr.jp/index.php?page=medic_facility)

tritis has a different etiology, only diseases produced by known pathogens, such as *H. pylori*, should be treated by targeting the pathogen directly. In addition, *H. pylori*-negative FD should not be categorized as so-called “chronic gastritis” because it is histologically negative for inflammation. As the pathophysiology underlying the disturbances of gastroduodenal motor and sensory functions and dyspepsia symptoms caused by *H. pylori* infection is gradually being elucidated, *H. pylori*-positive FD (i.e., HpD) should be considered an organic disease and dealt with as a disease entity distinct from FD⁵³ (Fig. 3). Separating HpD from FD may reconcile the conflicting results of previous studies on drug therapy for FD. The differences between the most effective therapeutic strategies against HpD and *H. pylori*-negative FD also require further investigation.

Indications for *H. pylori* Eradication in Japan

At present, *H. pylori* eradication is used not only for the treatment of peptic ulcer disease but also for prophylaxis and treatment of *H. pylori*-associated diseases such as gastric cancer, gastric MALT lymphoma, and ITP, as well as for inhibiting the spread of this bacterial infection.

H. pylori infection was approved as an official disease name in the 2003 edition of the International Statistical Classification of Diseases and Related Health Problems (ICD-10). *H. pylori* infection itself is soon expected to be accepted by the Japanese national health scheme as a disease entity; this will make the diagnosis and treatment of *H. pylori*-associated diseases a part of routine medical practice, resulting in the successful prevention of gastric cancer. In addition, *H. pylori* eradication therapy could

Table 2 Indications for *H. pylori* eradication therapy⁵⁴

	Diseases	Minds recommenda- tion grade	Level of evidence classification	Coverage by the Japanese national health insurance system
<i>H. pylori</i> infection	Peptic ulcer (gastric/duodenal ulcer)	A	I	Yes
	Gastric MALT lymphoma		III	Yes
	Idiopathic thrombocytopenic purpura (ITP)		I	Yes
	Patients after endoscopic treatment of early gastric cancer		II	Yes
	Atrophic gastritis		I	No
	Gastric hyperplastic polyps		II	No
	Functional dyspepsia (FD)		I	No
	Reflux esophagitis		II	No
	Iron-deficiency anemia		III	No
	Chronic urticaria		III	No

prevent the spread of this infection, which would lead to dramatic savings in medical costs.

According to the Guidelines for the Management of *Helicobacter pylori* Infection in Japan: 2009 Revised Edition of the Japanese Society of Helicobacter Research (JSHR),⁵⁴ *H. pylori* eradication has, based on strong evidence, been strongly recommended as level A (Minds Recommendation Grades) for all *H. pylori* infections. In the guidelines, the level of evidence for each recommendation was classified from Level I to Level VI. For example, peptic ulcer, ITP, atrophic gastritis, and FD were categorized as Level I [supported by systematic review and meta-analysis (Table 2)].⁵⁴ In contrast, early gastric cancer post-endoscopic treatment, gastric hyperplastic polyp, and reflux esophagitis were categorized as Level II (supported by at least one randomized controlled clinical trial), while gastric MALT lymphoma, iron-deficiency anemia, and chronic urticaria were categorized as Level III (supported by non-randomized controlled clinical studies) (Table 2).

Diagnosis of *H. pylori* Infection

H. pylori infection is investigated before and after eradication therapy using the following tests. Tests that require endoscopic biopsy include (i) the rapid urease test, (ii) histology, and (iii) culture, whereas tests not requiring endoscopic biopsy include (i) the ¹³C-urea breath test (UBT), (ii) detection of anti-*H. pylori* antibodies in the serum or urine, and (iii) measurement of *H. pylori* stool antigen. The national health insurance scheme now covers the use of two separate tests.⁵⁴

The rapid urease test has the advantages of low cost, ease of use, and speed, whereas the advantages of culture include 100% specificity (direct demonstration of the presence of *H. pylori*) and the ability to further character-

ize the organism (e.g., determination of its antibiotic susceptibility and investigation of its virulence factors). On the other hand, the UBT is a practical and readily available test with a diagnostic accuracy of >95%.

The detection of anti-*H. pylori* antibodies in the serum is a widely available and inexpensive test, but the diagnostic accuracy is low (80%–84%). Some highly accurate (90%) serology kits are recommended in validated settings.⁵⁵ The anti-urease activity of proton pump inhibitor (PPI) treatment can result in false-negative results for invasive and noninvasive diagnostic tests; therefore, PPI treatment should be withheld for at least 2 weeks before testing. However, this consideration does not apply to serology.

A systematic review of 89 studies evaluating the stool antigen test found an aggregate sensitivity and specificity of 91% and 93%, respectively.⁵⁶ Stool samples must be stored at –20°C prior to testing for this test to be accurate; the sensitivity of the stool antigen test decreases to 69% after storage of the samples at room temperature for 2–3 days. Stool antigen tests have low specificity in patients presenting with acute bleeding peptic ulcers, as there is cross-reactivity with blood products in the stool.

H. pylori Eradication Therapy

In Japan, 1 week of triple therapy using a PPI combined with amoxicillin (750 mg, b.i.d.) and clarithromycin (400 mg or 200 mg, b.i.d.) is recommended as the first-choice treatment for eradication of *H. pylori*.⁵⁷ At the 2008 meeting of the JSHR, the mean national clarithromycin resistance rates from 2002 to 2006 were reported to be 18.9%, 21.2%, 27.7%, 29.0%, and 27.2%. The mean nationwide clarithromycin resistance rate determined by the Japanese Society of Chemotherapy in 2000 was 7.0%, so the resistance rate has increased by approxi-

mately 20% over several years. Given the recent surge in clarithromycin resistance, new strategies for first-line treatment of *H. pylori* infection should be considered.⁵⁸ Recently, a European group performed a randomized, open-label, non-inferiority, phase 3 trial comparing the efficacy and safety of first-line quadruple therapy with omeprazole plus a single three-in-one capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline (quadruple therapy) for 10 days versus omeprazole, amoxicillin, and clarithromycin for 7 days (standard therapy) in adults with known *H. pylori* infection.⁵⁹ According to this study, the eradication rate in the intent-to-treat (ITT) population (n = 440) was 80% (174 of 218 participants) in the quadruple therapy group versus 55% (123 of 222) in the standard therapy group ($P < 0.0001$). This suggests that quadruple therapy would be considered for first-line treatment of *H. pylori* infection, especially in view of the rising prevalence of clarithromycin-resistant *H. pylori* and the fact that quadruple therapy provides superior eradication, with safety and tolerability similar to those of standard therapy, even though this study showed an extraordinarily low eradication rate in the standard therapy arm.⁵⁹ However, several issues, including the optimal doses of bismuth and amoxicillin and the duration of treatment, must be also considered before quadruple therapy can be established as the standard first-line therapy for *H. pylori* eradication.⁶⁰

In Japan, the recommended second-choice treatment for *H. pylori* infection is 1 week of triple therapy using a PPI combined with amoxicillin (750 mg, b.i.d.) and metronidazole (250 mg, b.i.d.). The prevalence of resistance to metronidazole in *H. pylori* in Japan has been reported to range between 5% and 12%.⁶¹ The Tokyo *H. pylori* Study Group examined the rate of eradication in response to the second-line regimen consisting of PPI, amoxicillin, and metronidazole in a multicenter study in the Tokyo metropolitan area.⁶² ITT and per-protocol (PP) analyses revealed eradication rates of 87.6% and 90.6%, respectively. Murakami *et al.* reported that eradication rates following second-line treatment of *H. pylori* infection with the PPI + amoxicillin + metronidazole regimen were 97% for infections with metronidazole-sensitive strains and 82% for infections with metronidazole-resistant strains. Two explanations are available for the discrepancy between the MICs for metronidazole and the eradication rates for PPI-amoxicillin-metronidazole triple therapy: (i) metronidazole is relatively stable under anaerobic conditions, possibly making its antimicrobial activity stronger in the stomach than *in vitro*, and (ii) the mechanism by which *H. pylori* acquires resistance to metronidazole remains unclear (mutations in the nitroreductase *rdxA* chromosome have been implicated, but there are other possibilities), making it difficult to predict the effects of metronidazole-containing second-line treatment regimens from the MIC of metronidazole alone. To improve prediction of eradication success by second-line treatment, we developed and

reported an eradication resistance index, calculated as: [Pre-treatment urea breath test result (%)] \times [amoxicillin MIC ($\mu\text{g}/\text{mL}$)] \times [metronidazole MIC ($\mu\text{g}/\text{mL}$)].⁶³ When a cutoff value of 3 was used, the eradication resistance index predicted the response to therapy with a specificity of 81.8%, a sensitivity of 93.8%, and an accuracy of 92.5%. However, because the superiority of the first-line eradication regimen (PPI + amoxicillin + clarithromycin) to the second-line regimen (PPI + amoxicillin + metronidazole) in Japan has recently been called into question, we retrospectively confirmed that the metronidazole-containing second-line regimen could be a superior primary eradication regimen for *H. pylori* in Japan.⁵⁸

There is at present no standard third-line treatment regimen for eradication of *H. pylori*, and European guidelines recommend culture before the selection of a third-line treatment to tailor the regimen to the antibiotic sensitivity of the isolate. *H. pylori* isolated after the failure of first- and second-line eradication regimens is often resistant to both metronidazole and clarithromycin.⁴⁶ Therefore, these two drugs are not recommended for inclusion in third-line regimens. In Japan, a PPI + amoxicillin + fluoroquinolone combination or high-dose PPI/amoxicillin therapy is recommended if second-line eradication therapy fails.^{54,64} However, we recently reported that even amoxicillin resistance (MIC $\geq 0.5 \mu\text{g}/\text{mL}$) is enhanced after multiple eradication failures (1st: 0%, 2nd: 0.9%, 3rd: 6.1%, and 4th: 18.2%) due to the accumulation of *PBP1* mutations.⁴⁶ Clinicians should therefore be aware of the possibility of resistance to amoxicillin along with that to other antibiotics.

Novel fluoroquinolones have recently been developed, and sitafloxacin has been reported to have superior *in vitro* activity against *H. pylori* compared with levofloxacin.^{65,66} We investigated the efficacy of sitafloxacin-based triple therapy as a third-line treatment administered after assessment of the isolates for sitafloxacin susceptibility and the presence of *gyrA* mutations. Sitafloxacin-based triple therapy achieved 83.6% (PP) or 78.2% (ITT) success among 78 Japanese patients. Even among the 47 patients with *gyrA* mutation-positive *H. pylori*, the eradication rates were 74.4% (PP) and 68.1% (ITT)⁶⁷. In that study, the position of the *gyrA* mutation (N87 or D91) was found to be superior to the MIC value for predicting the eradication outcome.⁶⁷ A randomized, open-label, parallel study comparing two sitafloxacin-based triple therapies in patients with multiple eradication failures is now underway in Keio University Hospital (Tokyo, Japan) (UMIN000006483) (http://kompas.hosp.keio.ac.jp/contents/medical_info/presentation/201201.html).

Summary

H. pylori infection is now known to be the main cause of peptic ulcer disease, chronic atrophic gastritis, and gastric MALT lymphoma, as well as non-cardia gastric cancer. In addition, an association between *H. pylori* infection and some extra-gastrointestinal diseases, such as ITP, has been indicated. We summarized recent basic research and clinical data on the link between *H. pylori* infection and *H. pylori*-associated diseases. Accurate diagnostic methods for *H. pylori* detection are available, allowing ready detection of the infection. Although the recommended first-line therapy regimens are effective and well tolerated, their wide use throughout the country over the years has led to failure of these regimens in 20%–30% of patients. Treatment failure is due mainly to increasing antibiotic resistance, in particular clarithromycin resistance. Although novel therapeutic strategies should be considered for first-line treatment, local monitoring of antimicrobial resistance must be implemented as well. In 2009, the JSHR established a board certification system for doctors treating *H. pylori* infection, and 734 doctors have been registered as a board-certified doctor by the JSHR after four board certification examinations on March 2012 (http://www.jshr.jp/index.php?page=medic_list) (Fig. 3). The JSHR also reported the list of institutes performing *H. pylori* eradication not covered by national insurance in Japan (http://www.jshr.jp/index.php?page=medic_facility) (Fig. 3).

While medical qualifications, scientific knowledge, and techniques in the field of *H. pylori* infection all continue to improve, the total control of these silent organisms in the stomach remains a challenge.

Acknowledgments

The present study was supported by a Grant-in-Aid for Scientific Research (B) from the Japan Society for the Promotion of Science (No. 22300169 to H.S.), a grant of the Adaptable and Seamless Technology Transfer Program through Target-Driven R & D (A-STEP) (AS231Z00132G to H.S.) from the Japan Science and Technology Agency (JST), a grant from the Smoking Research Foundation (to H.S.), the Keio Gijuku Academic Development Fund (to H.S.), and the Nateglinide Memorial Toyoshima Research and Education Fund (to H.S.).

References

- Suzuki H, Hibi T, Marshall BJ: *Helicobacter pylori*: present status and future prospects in Japan. *J Gastroenterol* 2007; **42**: 1–15. [Medline] [CrossRef]
- Palmer ED: Investigation of the gastric mucosa spirochetes of the human. *Gastroenterology* 1954; **27**: 218–220. [Medline]
- Kasai K, Kobayashi R: The stomach spirochete occurring in mammals. *J Parasitol* 1919; **6**: 1–10. [CrossRef]
- Saito K: Introductory remark of Dr. Rokuzo Kobayashi's achievements. *Keio J Med* 2002; **51**(Suppl 2): 2–3. [Medline]
- Suzuki H, Masaoka T, Miyazawa M, Suzuki M, Miura S, Ishii H: Gastric mucosal response to *Helicobacter pylori*. *Keio J Med* 2002; **51**(Suppl 2): 40–44. [Medline] [CrossRef]
- Suzuki M, Miura S, Suematsu M, Fukumura D, Kurose I, Suzuki H, Kai A, Kudoh Y, Ohashi M, Tsuchiya M: *Helicobacter pylori*-associated ammonia production enhances neutrophil-dependent gastric mucosal cell injury. *Am J Physiol* 1992; **263**: G719–G725. [Medline]
- Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M, Hatakeyama M: SHP-2 tyrosine phosphatase as an intracellular target of *Helicobacter pylori* CagA Protein. *Science* 2002; **295**: 683–686.
- Hatakeyama M: Oncogenic mechanisms of the *Helicobacter pylori* CagA protein. *Nat Rev Cancer* 2004; **4**: 688–694. [Medline] [CrossRef]
- Higashi H, Tsutsumi R, Fujita A, Yamazaki S, Asaka M, Azuma T, Hatakeyama M: Biological activity of the *Helicobacter pylori* virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. *Proc Natl Acad Sci USA* 2002; **99**: 14428–14433. [Medline] [CrossRef]
- Ishikawa S, Ohta T, Hatakeyama M: Stability of *Helicobacter pylori* CagA oncoprotein in human gastric epithelial cells. *FEBS Lett* 2009; **583**: 2414–2418. [Medline] [CrossRef]
- Tsugawa H, Suzuki H, Saya H, Hatakeyama M, Hirayama T, Hirata K, Nagano O, Matsuzaki J, Hibi T: Reactive oxygen species-induced autophagic degradation of *Helicobacter pylori* CagA is specifically suppressed in cancer stem-like cells. *Cell Host Microb* 2012; **12**: 764–777.
- Yamaoka Y: Mechanisms of disease: *Helicobacter pylori* virulence factors. *Nat Rev Gastroenterol Hepatol* 2010; **7**: 629–641. [Medline]
- Basso D, Navaglia F, Brigato L, Piva MG, Toma A, Greco E, Di Mario F, Galeotti F, Roveroni G, Corsini A, Plebani M: Analysis of *Helicobacter pylori* vacA and cagA genotypes and serum antibody profile in benign and malignant gastroduodenal diseases. *Gut* 1998; **43**: 182–186. [Medline] [CrossRef]
- Suzuki H, Iwasaki E, Hibi T: *Helicobacter pylori* and gastric cancer. *Gastric Cancer* 2009; **12**: 79–87. [Medline] [CrossRef]
- Farinati F, Cardin R, Russo VM, Busatto G, Franco M, Rugge M: *Helicobacter pylori* CagA status, mucosal oxidative damage and gastritis phenotype: a potential pathway to cancer? *Helicobacter* 2003; **8**: 227–234. [Medline] [CrossRef]
- Suzuki H, Suzuki M, Mori M, Kitahara T, Yokoyama H, Miura S, Hibi T, Ishii H: Augmented levels of gastric mucosal leucocyte activation by infection with cagA gene-positive *Helicobacter pylori*. *J Gastroenterol Hepatol* 1998; **13**: 294–300. [Medline] [CrossRef]
- Ding SZ, Minohara Y, Fan XJ, Wang J, Reyes VE, Patel J, Dirden-Kramer B, Boldogh I, Ernst PB, Crowe SE: *Helicobacter pylori* infection induces oxidative stress and programmed cell death in human gastric epithelial cells. *Infect Immun* 2007; **75**: 4030–4039. [Medline] [CrossRef]
- Perez-Reyes E, Kalyanaraman B, Mason RP: The reductive metabolism of metronidazole and ronidazole by aerobic liver microsomes. *Mol Pharmacol* 1980; **17**: 239–244. [Medline]
- Rao DN, Mason RP: Generation of nitro radical anions of some 5-nitrofurans, 2- and 5-nitroimidazoles by norepinephrine, dopamine, and serotonin. A possible mechanism for neurotoxicity caused by nitroheterocyclic drugs. *J Biol Chem* 1987; **262**: 11731–11736. [Medline]
- Spiegelhalter C, Gerstenecker B, Kersten A, Schiltz E, Kist M: Purification of *Helicobacter pylori* superoxide dismutase and cloning and sequencing of the gene. *Infect Immun* 1993; **61**: 5315–5325. [Medline]

21. Ernst FD, Homuth G, Stoof J, Mader U, Waidner B, Kuipers EJ, Kist M, Kusters JG, Bereswill S, van Vliet AH: Iron-responsive regulation of the *Helicobacter pylori* iron-cofactored superoxide dismutase SodB is mediated by Fur. *J Bacteriol* 2005; **187**: 3687–3692. [Medline] [CrossRef]
22. Tsugawa H, Suzuki H, Satoh K, Hirata K, Matsuzaki J, Saito Y, Suematsu M, Hibi T: Two amino acids mutation of ferric uptake regulator determines *Helicobacter pylori* resistance to metronidazole. *Antioxid Redox Signal* 2011; **14**: 15–23. [Medline] [CrossRef]
23. Esposito L, Seydel A, Aiello R, Sorrentino G, Cendron L, Zanotti G, Zagari A: The crystal structure of the superoxide dismutase from *Helicobacter pylori* reveals a structured C-terminal extension. *Biochim Biophys Acta* 2008; **1784**: 1601–1606. [Medline]
24. Tsugawa H, Suzuki H, Matsuzaki J, Hirata K, Hibi T: FecA1, a bacterial iron transporter, determines the survival of *Helicobacter pylori* in the stomach. *Free Radic Biol Med* 2012; **52**: 1003–1010. [Medline] [CrossRef]
25. Aldana LP, Kato M, Kondo T, Nakagawa S, Zheng R, Sugiyama T, Asaka M, Kwon DH: In vitro induction of resistance to metronidazole, and analysis of mutations in *rdxA* and *frxA* genes from *Helicobacter pylori* isolates. *J Infect Chemother* 2005; **11**: 59–63. [Medline]
26. Paulsen IT, Chen J, Nelson KE, Saier MH Jr: Comparative genomics of microbial drug efflux systems. *J Mol Microbiol Biotechnol* 2001; **3**: 145–150. [Medline]
27. van Amsterdam K, Bart A, van der Ende A: A *Helicobacter pylori* TolC efflux pump confers resistance to metronidazole. *Antimicrob Agents Chemother* 2005; **49**: 1477–1482. [Medline] [CrossRef]
28. Hirata K, Suzuki H, Nishizawa T, Tsugawa H, Muraoka H, Saito Y, Matsuzaki J, Hibi T: Contribution of efflux pumps to clarithromycin resistance in *Helicobacter pylori*. *J Gastroenterol Hepatol* 2010; **25**(suppl 1): S75–S79. [Medline] [CrossRef]
29. Tsugawa H, Suzuki H, Muraoka H, Ikeda F, Hirata K, Matsuzaki J, Saito Y, Hibi T: Enhanced bacterial efflux system is the first step to the development of metronidazole resistance in *Helicobacter pylori*. *Biochem Biophys Res Commun* 2011; **404**: 656–660. [Medline] [CrossRef]
30. Suzuki H, Nishizawa T, Tsugawa H, Mogami S, Hibi T: Roles of oxidative stress in stomach disorders. *J Clin Biochem Nutr* 2012; **50**: 35–39. [Medline] [CrossRef]
31. Suzuki H, Minegishi Y, Nomoto Y, Ota T, Masaoka T, van den Brink GR, Hibi T: Down-regulation of a morphogen (sonic hedgehog) gradient in the gastric epithelium of *Helicobacter pylori*-infected Mongolian gerbils. *J Pathol* 2005; **206**: 186–197. [Medline] [CrossRef]
32. Nishizawa T, Suzuki H, Masaoka T, Minegishi Y, Iwasaki E, Hibi T: *Helicobacter pylori* eradication restored sonic hedgehog expression in the stomach. *Hepatogastroenterology* 2007; **54**: 697–700. [Medline]
33. Nishizawa T, Suzuki H, Nakagawa I, Minegishi Y, Masaoka T, Iwasaki E, Hibi T: Early *Helicobacter pylori* eradication restores sonic hedgehog expression in the gastric mucosa of Mongolian gerbils. *Digestion* 2009; **79**: 99–108. [Medline] [CrossRef]
34. Nishizawa T, Suzuki H, Nakagawa I, Minegishi Y, Masaoka T, Iwasaki E, Hibi T: Rebamipide-promoted restoration of gastric mucosal sonic hedgehog expression after early *Helicobacter pylori* eradication. *Digestion* 2009; **79**: 259–262. [Medline] [CrossRef]
35. Saito Y, Suzuki H, Tsugawa H, Nakagawa I, Matsuzaki J, Kanai Y, and Hibi T: Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells. *Oncogene* 2009; **28**: 2738–2744
36. Belair C, Darfeuille F, Staedel C: *Helicobacter pylori* and gastric cancer: possible role of microRNAs in this intimate relationship. *Clin Microbiol Infect* 2009; **15**: 806–812. [Medline] [CrossRef]
37. Saito Y, Suzuki H, Hibi T: The role of microRNAs in gastrointestinal cancers. *J Gastroenterol* 2009; **44**(Suppl 19): 18–22. [Medline] [CrossRef]
38. Suzuki H, Saito Y, Hibi T: *Helicobacter pylori* and gastric mucosa-associated lymphoid tissue (MALT) lymphoma: updated review of clinical outcomes and the molecular pathogenesis. *Gut Liver* 2009; **3**: 81–87. [Medline] [CrossRef]
39. Takino H, Okabe M, Li C, Ohshima K, Yoshino T, Nakamura S, Ueda R, Eimoto T, Inagaki H: p16/INK4a gene methylation is a frequent finding in pulmonary MALT lymphomas at diagnosis. *Mod Pathol* 2005; **18**: 1187–1192. [Medline] [CrossRef]
40. Kaneko Y, Sakurai S, Hironaka M, Sato S, Oguni S, Sakuma Y, Sato K, Sugano K, Saito K: Distinct methylated profiles in *Helicobacter pylori* dependent and independent gastric MALT lymphomas. *Gut* 2003; **52**: 641–646. [Medline] [CrossRef]
41. Suzuki H, Franceschi F, Nishizawa T, Gasbarrini A: Extragastric manifestations of *Helicobacter pylori* infection. *Helicobacter* 2011; **16**(Suppl 1): 65–69. [Medline] [CrossRef]
42. Asahi A, Kuwana M, Suzuki H, Hibi T, Kawakami Y, Ikeda Y: Effects of a *Helicobacter pylori* eradication regimen on antiplatelet autoantibody response in infected and uninfected patients with idiopathic thrombocytopenic purpura. *Haematologica* 2006; **91**: 1436–1437. [Medline]
43. Asahi A, Nishimoto T, Okazaki Y, Suzuki H, Masaoka T, Kawakami Y, Ikeda Y, Kuwana M: *Helicobacter pylori* eradication shifts monocyte Fcγ receptor balance toward inhibitory FcγRIIB in immune thrombocytopenic purpura patients. *J Clin Invest* 2008; **118**: 2939–2949. [Medline]
44. Veneri D, Gottardi M, Guizzardi E, Zanuso C, Krampera M, and Franchini M: Idiopathic thrombocytopenic purpura, *Helicobacter pylori* infection, and HLA class II alleles. *Blood* 2002; **100**: 1925–1926; author reply 1926–1927.
45. Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, Stanghellini V: Functional gastroduodenal disorders. *Gastroenterology* 2006; **130**: 1466–1479. [Medline] [CrossRef]
46. Nishizawa T, Suzuki H, Tsugawa H, Muraoka H, Matsuzaki J, Hirata K, Ikeda F, Takahashi M, Hibi T: Enhancement of amoxicillin resistance after unsuccessful *Helicobacter pylori* eradication. *Antimicrob Agents Chemother* 2011; **55**: 3012–3014. [Medline] [CrossRef]
47. Miwa H, Ghoshal UC, Fock KM, Gonlachanvit S, Gwee KA, Ang TL, Chang FY, Hongo M, Hou X, Kachintorn U, Ke M, Lai KH, Lee KJ, Lu CL, Mahadeva S, Miura S, Park H, Rhee PL, Sugano K, Vilaichone RK, Wong BC, Bak YT: Asian Consensus Report on Functional Dyspepsia. *J Gastroenterol Hepatol* 2012; **27**: 626–641. [Medline]
48. Suzuki H, Nishizawa T, Hibi T: Can *Helicobacter pylori*-associated dyspepsia be categorized as functional dyspepsia? *J Gastroenterol Hepatol* 2011; **26**(Suppl 3): 42–45. [Medline] [CrossRef]
49. Saito Y, Suzuki H, Tsugawa H, Suzuki S, Matsuzaki J, Hirata K, Hibi T: Dysfunctional gastric emptying with down-regulation of muscle-specific microRNAs in *Helicobacter pylori*-infected mice. *Gastroenterology* 2011; **140**: 189–198. [Medline] [CrossRef]
50. Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, Oakes R, Wilson S, Roalfe A, Bennett C, Forman D: Eradication of *Helicobacter pylori* for non-ulcer dyspepsia. *Cochrane Database Syst Rev* 2006; CD002096. [Medline]
51. Suzuki H, Masaoka T, Sakai G, Ishii H, Hibi T: Improvement of gastrointestinal quality of life scores in cases of *Helicobacter pylori*-positive functional dyspepsia after successful eradication therapy. *J Gastroenterol Hepatol* 2005; **20**: 1652–1660. [Medline] [CrossRef]
52. Sugano K: Should we still subcategorize *Helicobacter pylori*-associated dyspepsia as functional disease? *J Neurogastroenterol Motil* 2011; **17**: 366–371. [Medline] [CrossRef]

53. Suzuki H, Matsuzaki J, Hibi T: What is the difference between *Helicobacter pylori*-associated dyspepsia and functional dyspepsia? *J Neurogastroenterol Motil* 2011; **17**: 124–130. [Medline] [CrossRef]
54. Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, Uemura N, Murakami K, Satoh K, Sugano K: Guidelines for the management of *Helicobacter pylori* infection in Japan: 2009 revised edition. *Helicobacter* 2010; **15**: 1–20.
55. Laheij RJ, Straatman H, Jansen JB, Verbeek AL: Evaluation of commercially available *Helicobacter pylori* serology kits: a review. *J Clin Microbiol* 1998; **36**: 2803–2809. [Medline]
56. Gisbert JP, Pajares JM: Stool antigen test for the diagnosis of *Helicobacter pylori* infection: a systematic review. *Helicobacter* 2004; **9**: 347–368. [Medline] [CrossRef]
57. Suzuki H, Masaoka T, Nomura S, Hoshino Y, Kurabayashi K, Minegishi Y, Suzuki M, Ishii H: Current consensus on the diagnosis and treatment of *H. pylori*-associated gastroduodenal disease. *Keio J Med* 2003; **52**: 163–173. [Medline] [CrossRef]
58. Nishizawa T, Suzuki H, Suzuki M, Takahashi M, Hibi T: PPI-amoxicillin-clarithromycin versus PPI-amoxicillin-metronidazole as first-line *Helicobacter pylori* eradication therapy. *J Clin Biochem Nutr* 2012; **51**: 114–116.
59. Malfertheiner P, Bazzoli F, Delchier JC, Celinski K, Giguere M, Riviere M, Megraud F: *Helicobacter pylori* eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. *Lancet* 2011; **377**: 905–913. [Medline] [CrossRef]
60. Suzuki H, Matsuzaki J, Hibi T: Metronidazole-based quadruple versus standard triple therapy: which is better as first-line therapy for *Helicobacter pylori* eradication? *Expert Rev Clin Pharmacol* 2011; **4**: 579–582. [Medline] [CrossRef]
61. Hiyama T, Tanaka S, Masuda H, Shima H, Kose K, Tuncel H, Ito M, Kitadai Y, Sumii M, Uemura N, Yoshihara M, Shimamoto F, Haruma K, Chayama K: Prevalence of *Helicobacter pylori* resistance to clarithromycin and metronidazole determined by 23S ribosomal RNA and rdxA gene analyses in Hiroshima, Japan. *J Gastroenterol Hepatol* 2003; **18**: 1202–1207. [Medline] [CrossRef]
62. Matsuhisa T, Kawai T, Masaoka T, Suzuki H, Ito M, Kawamura Y, Tokunaga K, Suzuki M, Mine T, Takahashi S, Sakaki N: Efficacy of metronidazole as second-line drug for the treatment of *Helicobacter pylori* infection in the Japanese population: a multi-center study in the Tokyo Metropolitan Area. *Helicobacter* 2006; **11**: 152–158. [Medline] [CrossRef]
63. Nishizawa T, Suzuki H, Masaoka T, Iwasaki E, Hibi T: A new eradication resistance index as a predictor of metronidazole-containing second-line treatment of *Helicobacter pylori*. *Digestion* 2007; **76**: 215–220. [Medline] [CrossRef]
64. Nishizawa T, Suzuki H, Nakagawa I, Iwasaki E, Masaoka T, Hibi T: Gatifloxacin-based triple therapy as a third-line regimen for *Helicobacter pylori* eradication. *J Gastroenterol Hepatol* 2008; **23**(Suppl 2): S167–S170. [Medline] [CrossRef]
65. Suzuki H, Nishizawa T, Muraoka H, Hibi T: Sitafloxacin and garenoxacin may overcome the antibiotic resistance of *Helicobacter pylori* with gyrA mutation. *Antimicrob Agents Chemother* 2009; **53**: 1720–1721. [Medline] [CrossRef]
66. Nishizawa T, Suzuki H, Hibi T: Quinolone-based third-line therapy for *Helicobacter pylori* eradication. *J Clin Biochem Nutr* 2009; **44**: 119–124. [Medline] [CrossRef]
67. Matsuzaki J, Suzuki H, Nishizawa T, Hirata K, Tsugawa H, Saito Y, Okada S, Fukuhara S, Hibi T: Efficacy of sitafloxacin-based rescue therapy for *Helicobacter pylori* after failures of first- and second-line therapies. *Antimicrob Agents Chemother* 2012; **56**: 1643–1645. [Medline] [CrossRef]

Enhanced Gastric Ghrelin-Induced c-Kit Protein Expression in Rats with Gastric Outlet Obstruction

Eisuke Iwasaki · Hidekazu Suzuki ·
Sachiko Mogami · Toshifumi Hibi

Received: 1 October 2012 / Accepted: 3 October 2012 / Published online: 23 October 2012
© Springer Science+Business Media New York 2012

Dear Editor,

We reported in the April issue of *Digestive Diseases and Sciences* that rats with gastric outlet obstruction (GOO) had an enhanced mRNA expression of c-kit, a marker of interstitial cells of Cajal (ICC), in the stomach with an increased level of ghrelin production [1]. However, the distribution of c-Kit protein expression in the stomach was not shown. Now, we have completed the additional experiments to clarify this point.

For histochemical staining of c-Kit, stomach tissue specimens were fixed with cold acetone for 30 min and embedded in Tissue-Tek OCT compound 4583 (Sakura Finetechnical, Tokyo, Japan), frozen in liquid isopentane cooled with liquid nitrogen, and cut into 5- μ m sections with a cryostat (CM1850; Leica, Nussloch, Germany). The sections were placed on a microslide glass (Matsunami, Osaka, Japan) and incubated with Protein Block (DAKO Japan, Tokyo, Japan) containing 0.5 % Triton X-100 for 1 h at room temperature and incubated with rabbit anti-c-Kit polyclonal antibody (A4502; 1:200, Daco Japan) overnight at 4 °C. Immunoreactivity was detected using

Alexa Fluor 488 donkey anti-rabbit IgG (1:1,000; Invitrogen, Eugene, OR, USA). Coverslips were mounted with Permafluor (Beckman Coulter, Fullerton, CA, USA) and immunofluorescence was examined using a keyence BIOZERO (Keyence, Osaka, Japan) [2].

Now, we showed the enhanced levels of c-Kit immunoreactive cells in rats with GOO (Fig. 1a). The areas of the c-Kit-positive cells were quantified in 12 microscopic fields from each individual rat using the ImageJ program (National Institutes of Health). For the measurement of ICC-IM (intramuscular ICC)-positive levels, the area of the c-Kit-positive cells in the muscular layers was normalized with the whole area of inner circular muscular layers. For the measurement of ICC-MY (myenteric ICC)-positive levels, the area of the c-Kit-positive cells in the myenteric plexus was normalized with the whole area of intermuscular space. By the morphometric analyses, in the GOO group, the levels of ICC-IM as well as ICC-MY, in both the antrum and the corpus, were quantified (Fig. 1b). After intraperitoneal injection of [D-Lys3] GHRP-6, a ghrelin receptor antagonist, (6.0 mg/kg; Bachem, PA, USA), both the levels of ICC-IM and ICC-MY were decreased in the antrum and the corpus. It is concluded that GOO enhances c-Kit expression through the enhancement of ghrelin in the stomach.

In the present experiment, we performed histopathologic sampling of the specimen 30 min after administration of ghrelin receptor antagonist, since Miyazawa et al. [3] reported that the biological half-time of c-Kit protein was 30–60 min in the cultured cells.

The enhancement of immunoreactivity of c-Kit protein was shown not only in the ICC-IM but also in the ICC-MY. Our results indicate that enhanced ghrelin keeps the expression of the mRNA and the protein expression of c-Kit at high levels in rats with GOO.

E. Iwasaki · H. Suzuki (✉) · S. Mogami · T. Hibi
Division of Gastroenterology and Hepatology, Department
of Internal Medicine, School of Medicine, Keio University,
35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
e-mail: hsuzuki@a6.keio.jp

E. Iwasaki
Department of Internal Medicine, Saiseikai Central Hospital,
1-4-17 Mita, Minato-ku, Tokyo 108-0073, Japan




Fig. 1 **a** Immunofluorescent staining of c-Kit in the corpus and the antrum of sham-operated control rats and GOO rat and GOO rats with [D-lys3] GHRP-6. **b** Areas of ICC-IM and ICC-MY were quantified

by image analysis and are shown ($n = 6$, each group). Data are mean \pm SD. * $P < 0.05$ compared to control rats, † $P < 0.05$ compared to GOO rats

References

1. Iwasaki E, Suzuki H, Masaoka T, et al. Enhanced gastric ghrelin production and secretion in rats with gastric outlet obstruction. *Dig Dis Sci.* 2012;57:858–864.
2. Suzuki S, Suzuki H, Horiguchi K, et al. Delayed gastric emptying and disruption of the interstitial cells of Cajal network after gastric

- ischaemia and reperfusion. *Neurogastroenterol Motil.* 2010;22: 585–93, e126.
3. Miyazawa K, Williams DA, Gotoh A, Nishimaki J, Broxmeyer HE, Toyama K. Membrane-bound steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form. *Blood.* 1995;85: 641–649.

HEPATOLOGY

Effect of ursodeoxycholic acid and endoscopic sphincterotomy in long-term stenting for common bile duct stonesToshihiro Nishizawa,*[†] Hidekazu Suzuki,[†] Masahiko Takahashi,* Hiroshi Kaneko,* Masayuki Suzuki* and Toshifumi Hibi[†]*Division of Gastroenterology, National Hospital Organization Tokyo Medical Center, Meguro-ku, and [†]Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan**Key words**

biliary stent, common bile duct (CBD) stones, endoscopic sphincterotomy, ursodeoxycholic acid.

Accepted for publication 3 October 2012.

Correspondence

Dr Hidekazu Suzuki, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Email: hsuzuki@a6.keio.jp

Abstract**Background and Aim:** We investigated the patency rate of a biliary stent and the effects of ursodeoxycholic acid (UDCA) therapy and endoscopic sphincterotomy (EST) for difficult-to-remove common bile duct stones.**Method:** A total of 63 endoscopic retrograde cholangiopancreatographies (ERCPs) were performed in 36 patients (mean age, 86.0 years; male–female, 17:19) for stenting. Among the 63 subjects, 28 were further treated with EST; 20, with UDCA therapy; and 43, without UDCA therapy.**Results:** The mean patency time was significantly longer in the UDCA treatment group (1,012 days) than in the “stent without UDCA” group (354 days; $P = 0.0002$; hazard ratio, 0.253). The mean patency time was significantly longer in the patients who had stent placement with EST (1074 days) than in those who had stent placement without EST (279 days; $P = 0.001$; hazard ratio, 0.439). The mean patency time was significantly longer in the patients who had stent placement with UDCA therapy and EST (1211 days) than in the patients who had stent placement with either UDCA therapy or EST (425 days; $P = 0.031$; hazard ratio, 0.3292). The mean patency time was significantly longer in the patients who had stent placement with either UDCA therapy or EST than in those who had stent placement without UDCA therapy or EST (263 days; $P = 0.0465$; hazard ratio, 0.5124).**Conclusion:** Biliary stenting combined with UDCA therapy and EST may be considered as an effective treatment method for cases of common bile duct stones in elderly patients that are difficult to remove.**Introduction**

Stone extraction after endoscopic sphincterotomy (EST) is considered the current standard treatment for common bile duct (CBD) stones. The treatment success rate is approximately 90% when using a combination of basket and balloon catheter and lithotripsy.¹ However, in some cases in elderly patients who are clinically unfit for the complicated endoscopic retrograde cholangiopancreatography (ERCP) procedure, biliary stenting is an option, and its short-term effect has been proven.² However, the long-term benefit of stenting is unclear. In the present study, we investigated the long-term outcome and patency rate of biliary stents, and the effects of ursodeoxycholic acid (UDCA) therapy and additional EST for CBD stones.

Method

We retrospectively reviewed the medical case charts of patients who underwent stent placement for CBD stones between 1

January 2003 and 30 April 2012. Patients were identified from a computerized database listing of all patients who underwent an endoscopic procedure at the National Tokyo Medical Center.

Thirty-six patients had difficult-to-remove CBD stones. The CBD stones were too large for successful endoscopic extraction or the patients too frail and elderly for further frequent attempts. Biliary drainage was achieved by inserting a single 7- (7 or 10 cm) or 6-Fr (7 or 10 cm) double pigtail stent (Cook Japan, Tokyo) with the proximal end at the portion just above the stones and the distal end in the duodenum. In the patients who were receiving antiplatelet or anticoagulant therapy and those with intradiverticular papilla, EST was not performed. The UDCA medication was chosen at the clinician's discretion. After the endoscopic procedures, all the patients were informed of the possible complications related to long-term biliary stent placement and were advised to contact our hospital if symptoms suggestive of cholangitis or jaundice occurred. Stent replacement was performed when symptoms of cholangitis occurred and/or elevated alkaline phosphatase or

bilirubin levels recurred. The period until the symptoms occurred was defined as stent patency time.

Differences between the groups were compared using the Student *t*-test for continuous variables and the Fisher exact test or chi-squared test for categorical variables. The patency rate and time to treatment failure were analyzed using the log-rank test and presented as Kaplan–Meier estimates with the hazard ratio and 95% confidence intervals (CIs).

Results

During the study period, a total of 63 ERCP procedures for stenting were performed in 36 patients (age, 86.0 ± 6.78 years; male–female, 17:19), of whom 28 also underwent EST. One ERCP procedure was performed in 21 patients, two ERCP procedures were performed in 10 patients, three ERCP procedures were




Figure 1 Patients’ demographic data.

Table 1 Characteristics of the patients who underwent stent placement with or without ursodeoxycholic acid (UDCA) therapy

	Stent with UDCA (20 procedures)	Stent without UDCA (43 procedures)	P value
Age (mean ± SD, years)	87.6 ± 4.1	85.5 ± 7.4	0.25
Male–female	11/9	23/20	0.91
Stent, 6 Fr/7 Fr	7/13	14/29	0.84
Stent, 7 cm/10 cm	11/9	26/17	0.68
With/without EST	11/9	17/26	0.38
Size of stones (mm)	15.3 ± 8.1	14.0 ± 7.8	0.56
Number of stones	4.3 ± 2.3	3.6 ± 1.6	0.14
Mean patency time (days)	1012.0	354.1	0.0002
1-year patency rate	62.5%	31.7%	
6-month patency rate	80%	48.3%	

EST, endoscopic sphincterotomy.




Figure 2 Biliary stent patency in the patients who did or did not receive ursodeoxycholic acid (UDCA) therapy.

Table 2 Characteristics of the patients who underwent stent placement with or without endoscopic sphincterotomy (EST)

	Stent with EST (28 procedures)	Stent without EST (35 procedures)	<i>P</i> value
Age (mean ± SD, years)	84.9 ± 7.4	87.1 ± 5.7	0.19
Male/female	12/16	22/13	0.11
Stent, 6 Fr/7 Fr	8/20	13/22	0.47
Stent 7 cm/10 cm	13/15	24/11	0.08
With/without UDCA	11/17	9/26	0.25
Size of stones (mm)	15.0 ± 9.5	14.0 ± 6.4	0.64
Number of stones	3.5 ± 2.0	4.0 ± 1.8	0.26
Mean patency time	1074.2	279.0	0.001
1-year patency rate	59.0%	33.4%	
6-month patency rate	69.9%	47.9%	

UDCA, ursodeoxycholic acid.




Figure 3 Biliary stent patency in the patients who underwent or did not undergo endoscopic sphincterotomy (EST).

performed in 2 patients, four ERCP procedures were performed in 2 patients, and eight ERCP procedures were performed in 1 patient (mean 1.75 sessions of ERCP). After undergoing ERCPs for stenting, 20 subjects were treated with UDCA (600 and 300 mg/day in 12 and 8 subjects, respectively), whereas 43 did not receive UDCA (Fig. 1). There was no stent dislodge. There were eight deaths due to unrelated causes. Four patients dropped out of the study because they were transferred to other hospitals.

The baseline characteristics of the patients who had stent placement with and without UDCA treatment were similar (Table 1). The mean patency time was significantly longer in the UDCA treatment group (1,012 days) than in the “stent without UDCA” group (354.1 days; *P* = 0.0002; hazard ratio, 0.253; 95% CI, 0.0283–0.3319; Fig. 2).

The baseline characteristics of the patients who had stent placement with and without EST were similar (Table 2). The mean

patency time was significantly longer in the “stent with EST” group (1,074.2 days) than in the “stent without EST” group (279 days; *P* = 0.001; hazard ratio, 0.439; 95% CI, 0.2121–0.8155; Fig. 3).

The characteristics of the patients who had stent replacement with UDCA therapy and EST, with either UDCA therapy or EST, or without UDCA therapy or EST are outlined in Table 3. The mean patency time was significantly longer in the “stent with UDCA therapy and EST” group (1211.9 days) than in the “stent with either UDCA therapy or EST” group (425.8 days; *P* = 0.031; hazard ratio, 0.3292; 95% CI, 0.1381–0.90734). The mean patency time was significantly longer in the “stent with either UDCA therapy or EST” group (425.8 days) than in the “stent without UDCA therapy or EST” group (263.4 days; *P* = 0.0465; hazard ratio, 0.5124; 95% CI, 0.2352–0.988915; Fig. 4).

Table 3 Impact of ursodeoxycholic acid (UDCA) therapy and endoscopic sphincterotomy (EST) on the biliary stents

	Stent with UDCA and EST (11 procedures)	Stent with either UDCA or EST (26 procedures)	Stent without UDCA or EST (26 procedures)	P value
Age (mean \pm SD, years)	86.5 \pm 4.9	85.6 \pm 7.4	86.6 \pm 6.4	0.84
Male/female	4/7	17/9	8/18	0.03
Stent 6 Fr/7 Fr	5/6	5/21	11/15	0.14
Stent 7 cm/10 cm	4/7	16/10	17/9	0.24
Size of stones (mm)	16.2 \pm 8.9	14.2 \pm 9.1	14.0 \pm 6.1	0.14
Number of stones	4.3 \pm 2.3	3.2 \pm 1.8	3.9 \pm 1.8	0.52
Mean patency time (days)	1211.9	425.8	263.4	0.031 [†] 0.047 [‡]
1-year patency rate	70.1%	44.7%	26.0%	
6-month patency rate	81.8%	60.6%	41.6%	

[†]Stent with UDCA and EST versus stent with either UDCA therapy or EST.

[‡]Stent with either UDCA or EST versus stent without UDCA therapy or EST.




Figure 4 Biliary stent patency in the patients who underwent stent placement with ursodeoxycholic acid (UDCA) therapy and endoscopic sphincterotomy (EST). (A) Patients who underwent stent placement with UDCA therapy and EST. (B) Patients who underwent stent placement with either UDCA therapy or EST. (C) Patients who underwent stent placement without UDCA therapy or EST.

Discussion

This is the first report indicating that the combination of UDCA therapy and EST with biliary stenting is effective for treating elderly patients with CBD stones that are difficult to remove.

UDCA has been used to dissolve gallstones. UDCA, a hydrophilic dihydroxy bile acid ($3\alpha,7\beta$ -dihydroxy-5 β -cholanoic acid), reduces the lithogenicity of bile by decreasing the biliary lipid output composed of cholesterol.³ A report by Johnson *et al.*⁴ emphasized the supplementary use of UDCA in cleaning the bile duct. Nine of 10 patients who were treated with concomitant UDCA therapy showed complete clearance of CBD stones 9

months after biliary stenting, whereas 10 patients who received biliary stent alone showed only partial clearance. However, in a recent randomized blinded trial of the combination of plastic biliary stents and 750-mg/day oral UDCA or placebo for 6 months, there was no significant difference in the clearance of CBD stones (76.9% vs 75.0%, respectively) and stone size reduction (0.40 vs 0.37 cm, respectively) between the two groups.⁵ However, in long-term biliary stenting, our data showed a beneficial effect of the UDCA therapy on the stent patency rate.

The biliary stent is not considered as the sole conduit for bile flow when used for CBD stones. As expected, a free space remains in the CBD after biliary stent placement alongside the stones,

possibly providing a pathway for bile flow even when the biliary stent is completely obstructed.⁶ EST may provide an additional outflow pathway. In all patients requiring stenting for CBD stones, we suggest that EST should be performed because complications such as cholangitis are more frequent in patients who had not undergone EST.

The limitations of this study include the small number of patients and nonrandomized retrospective study design. To validate our results, a randomized prospective study comparing the results of biliary stenting only with those of biliary stenting combined with UDCA therapy and EST is required.

In conclusion, based on our results, biliary stenting combined with UDCA therapy and EST may be considered a safe and effective method for treating elderly patients with CBD stones that are difficult to remove.

Acknowledgment

This study was supported by a grant from the National Hospital Organization (No. H24-NHO [gastroenterology]-01, to T.N.).

References

- 1 Hochberger J, Tex S, Maiss J, Hahn EG. Management of difficult common bile duct stones. *Gastrointest. Endosc. Clin. North Am.* 2003; **13**: 623–34.
- 2 Li KW, Zhang XW, Ding J, Chen T, Wang J, Shi WJ. A prospective study of the efficacy of endoscopic biliary stenting on common bile duct stones. *J. Dig. Dis.* 2009; **10**: 328–31.
- 3 Han J, Moon JH, Koo HC *et al.* Effect of biliary stenting combined with ursodeoxycholic acid and terpene treatment on retained common bile duct stones in elderly patients: a multicenter study. *Am. J. Gastroenterol.* 2009; **104**: 2418–21.
- 4 Johnson GK, Geenen JE, Venu RP, Schmalz MJ, Hogan WJ. Treatment of non-extractable common bile duct stones with combination ursodeoxycholic acid plus endoprosthesis. *Gastrointest. Endosc.* 1993; **39**: 528–31.
- 5 Katsinelos P, Kountouras J, Paroutoglou G, Chatzimavroudis G, Zavos C. Combination of endoprosthesis and oral ursodeoxycholic acid or placebo in the treatment of difficult to extract common bile duct stones. *Dig. Liver Dis.* 2008; **40**: 453–9.
- 6 Kubota Y, Takaoka M, Fujimura K *et al.* Endoscopic endoprosthesis for large stones in the common bile duct. *Intern. Med.* 1994; **33**: 597–601.

Reactive Oxygen Species-Induced Autophagic Degradation of *Helicobacter pylori* CagA Is Specifically Suppressed in Cancer Stem-like Cells

Hitoshi Tsugawa,¹ Hidekazu Suzuki,^{1,*} Hideyuki Saya,² Masanori Hatakeyama,³ Toshiya Hirayama,⁴ Kenro Hirata,¹ Osamu Nagano,² Juntaro Matsuzaki,¹ and Toshifumi Hibi¹

¹Division of Gastroenterology and Hepatology, Department of Internal Medicine

²Division of Gene Regulation, Institute for Advanced Medical Research
Keio University School of Medicine, Tokyo 160-8582, Japan

³Division of Microbiology, Graduate School of Medicine, University of Tokyo, Tokyo 113-0033, Japan

⁴Department of Bacteriology, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan

*Correspondence: hsuzuki@a6.keio.jp

<http://dx.doi.org/10.1016/j.chom.2012.10.014>

SUMMARY

Sustained expression of CagA, the type IV secretion effector of *Helicobacter pylori*, is closely associated with the development of gastric cancer. However, we observed that after translocation, CagA is degraded by autophagy and therefore short lived. Autophagy and CagA degradation are induced by the *H. pylori* vacuolating cytotoxin, VacA, which acted via decreasing intracellular glutathione (GSH) levels, causing reactive oxygen species (ROS) accumulation and Akt activation. Investigating this further, we found that CagA specifically accumulated in gastric cells expressing CD44, a cell-surface marker associated with cancer stem cells. The autophagic pathway in CD44-positive gastric cancer stem-like cells is suppressed because of their resistance to ROS, which is supported by increased intracellular GSH levels. These findings provide a molecular link between *H. pylori* and gastric carcinogenesis through the specific accumulation of CagA in gastric cancer stem-like cells.

INTRODUCTION

A possible link has been demonstrated between *Helicobacter pylori* infection and development of gastric cancer by epidemiological (Uemura et al., 2001) and animal studies (Suzuki et al., 2009). Although long-term *H. pylori* infections of the gastric mucosa might cause gastric cancer from severe inflammation, no direct molecular link was demonstrated until Hatakeyama reported that the transfer of *H. pylori*-derived CagA to epithelial cells through a bacterial type IV secretion system promoted an early event of gastric carcinogenesis (Hatakeyama, 2004). Ohnishi et al. (2008) also demonstrated that systemic expression of CagA in *cagA*-transgenic mice induced gastrointestinal malignancies, indicating the oncogenic potential of bacterial CagA in mammals. However, it was also reported that CagA, after translocation to gastric epithelial cells, does not persist for a long period (Ishikawa et al., 2009).

Recently, it has been reported that autophagy—a system for bulk protein degradation and the elimination of invaded pathogens (Deretic and Levine, 2009)—is induced in *H. pylori*-infected cells (Raju et al., 2012; Terebiznik et al., 2009). In the present study, we observed that intracellular CagA was degraded by autophagy induced by the accumulation of reactive oxygen species (ROS), suggesting that CagA may not promote carcinogenesis. Even if CagA escapes the autophagy system, intracellular CagA could never be transferred to daughter cells and would be lost after cell division. If translocated CagA does indeed trigger gastric carcinogenesis, it should be transferred to slow-cycling master-regulator cells and escape from autophagic degradation.

CD44 is a cell-surface marker associated with cancer stem cells in various tumors (Dalerba et al., 2007). Gastric cancer stem-like cells expressing the variant isoform of CD44 (CD44v9) suppress ROS accumulation by control of intracellular glutathione (GSH) levels by stabilizing xCT, a cystine transporter (Ishimoto et al., 2011). In the present report, we used CD44v9-expressing gastric cancer stem-like cells to study the ability of intracellular CagA to escape from autophagy and show a direct molecular link between *H. pylori*-derived CagA and gastric cancer stem-like cells.

RESULTS

CagA Is Degraded by Autophagy

To investigate the stability of intracellular CagA, we constructed an in vitro *H. pylori* infection model using a gastric cancer cell line (AGS). After 5 hr of *H. pylori* ATCC700392 infection, the AGS cells were incubated with kanamycin to kill extracellular bacteria. In AGS cells after *H. pylori* eradication, the levels of intracellular CagA and tyrosine-phosphorylated CagA (p-CagA) decreased in a time-dependent manner (Figure 1A). Therefore, intracellular CagA did not persist for a prolonged period in gastric epithelial cells and was soon degraded by host cell defenses.

To examine the mechanism of CagA degradation in host epithelial cells, we used proteasome inhibitors (MG132 and lactacystin [Lact]) and autophagy inhibitors (3-methyladenine [3MA] and wortmannin [Wort]). At 24 hr after *H. pylori* ATCC700392 eradication, while intracellular CagA and p-CagA levels were